MOUNTAIN VIEW, Calif., Aug. 21, 2013 /PRNewswire/ -- Based on its recent analysis of the mobile health applications market for asthma management, Frost & Sullivan recognizes iSonea Limited with the 2013 North American Frost & Sullivan Award for New Product Innovation Leadership. iSonea combined its mobile application, AsthmaSense®, with the AsthmaSense Cloud to provide a convenient solution to patients, caregivers and physicians for remote monitoring of asthma symptoms and events. Using AsthmaSense Cloud to help asthma management can make patients more aware of their symptoms, triggers, and potential risks, encouraging adherence to their treatment plans.
The AsthmaSense mobile app tracks asthma symptoms (signs of breathing function, medication usage) and the treatment plan. Used in conjunction with the company's proprietary Acoustic Respiratory Monitoring (ARM™) system, the app is evolving to integrate wheeze monitoring into the risk-sensing equation, as well as the user's geographical location, weather, and air quality factors that may affect asthma patients.
In order to facilitate the continuous monitoring and data security of the asthma patient's condition, iSonea upgraded the AsthmaSense app with an integrative cloud storage database platform to offer enhancements in mobile asthma monitoring services. The AsthmaSense Cloud software is currently integrated with lung capacity measurements from Peak Flow Meters and/or spirometry.
"The interpretation of cloud-based data and communication systems enables physicians to recall relevant events, trends, and measurements of response to treatment when the patient is exposed to various conditions leading to an asthmatic attack," said Frost & Sullivan Industry Analyst Vin Nee Lim. "Linking the AsthmaSense Cloud with the AsthmaSense app enables the asthma event monitoring data to automatically store the data and responses entered by the user in a password-protected cloud vault transfer, which is easily accessible by the users on personal computers."
The AsthmaSense app displays "hint bubbles" on the phone screen for a smooth operating experience. It also provides health practitioners and caregivers with a real-time framework for monitoring asthma patients and, consequently, offers feedback for managing asthma. For instance, the app can alert the patient or caregiver to increasing risk of an asthma event, based on National Heart Lung & Blood Institute (NHLBI) guidelines for asthma control, by factoring in symptoms, behavior, medication usage, and external triggers. Furthermore, the cloud storage feature aids improved collection, storage and interpretation of large amounts of patient data, which can be retrieved in case the user's phone is lost, damaged, or exchanged.
"In comparison to other competing solutions, adapting iSonea's asthma monitoring technology to the smartphone provides an easier and more convenient means of data collection, analysis, and communication," noted Vin Nee. "AsthmaSense app and AsthmaSense Cloud's data compilation of users' asthma events clearly illustrate the 'cause and effect' by mapping the lifestyle, environmental, and physiological causes of asthma attacks."
AsthmaSense app's programmable reminders and alerts can potentially improve patient adherence to asthma management. This can lead to more diligent monitoring of risks in real-life settings.
Each year, Frost & Sullivan presents this award to the company that has developed an innovative element in a product by leveraging leading-edge technologies. The award recognizes the value-added features/benefits of the product and the increased ROI it offers customers, which, in turn, increases customer acquisition and overall market penetration potential.
Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.
iSonea Limited (ASX:ISN) is an emerging medical technology company developing innovative, non-invasive devices and mobile health apps to improve the management of chronic, costly respiratory disorders such as asthma and COPD. By leveraging iSonea's proprietary Acoustic Respiratory Monitoring™ (ARM) technology with its AsthmaSense® mobile applications, iSonea is turning smart phones into monitoring devices--enabling anyone, anywhere, at any time to monitor breathing symptoms and to adhere to treatment plans. iSonea's ARM devices have been cleared for use by the U.S. Food and Drug Administration, the Australian TGA and the European Union CE.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
P: 210. 247.3870
iSonea Media Contact:
|SOURCE Frost & Sullivan|
Copyright©2012 PR Newswire.
All rights reserved